UK: PLGA Particle Production Dolomite Microfluidics to Develop Off-the-Shelf Microfluidic Device Kits
Dolomite Microfluidics has partnered with Millipore Sigma to release new Nano Fabtx kits which will be used for the fabrication of PLGA particles for drug development and controlled drug release applications.
UK – Dolomite Microfluidics and Millipore Sigma have partnered to create a range of off-the-shelf Nano Fabtx microfluidic device kits for the production of PLGA nano- and microparticles for drug development and controlled drug release applications. The kits – which will be available exclusively from Millipore Sigma – are also ideal for the encapsulation of drugs and other therapeutics in liposomes, such as the Sars-Cov-2 (Covid-19) vaccines currently under investigation.
The increasing use of biodegradable PLGA polymers for drug encapsulation and formulation of controlled release preparations has created a market for easy-to-use, ready-to-go microfluidic solutions that simplify the workflow for researchers. The new Nano Fabtx kits include a microfluidic chip, holders and accessories, along with application data for the production of a variety of particle types and sizes; simply connect the kit to the pumps and start your application. This user-friendly microfluidic approach offers better encapsulation efficiency and higher monodispersity than traditional methods.
Particles of the correct dimensions can be isolated without wasteful filtering, ensuring the tight control of size and shape that is essential to regulate the speed of drug delivery and release. The new kits are intended for use with Millipore Sigma’s Nano Fabtx PLGA-Nano and Nano Fabtx PLGA-Micro Reagent kits, and are perfectly optimised for microfluidic pumps and software from Dolomite to give high accuracy and consistency. The kits can also be combined with Dolomite’s high throughput Telos technology for scaled up experiments.
Richard Gray, Commercial Director at Dolomite Microfluidics, commented: “Millipore Sigma chose Dolomite Microfluidics because of our reputation and many years’ expertise in providing excellent microfluidic solutions that deliver consistent and reliable production of particles. The controllability and reproducibility that microfluidics offers means the process is really finding its place in drug and vaccine development, making it the method of choice. We are looking forward to continuing our work with scientists to keep getting particles out there at the forefront of this area.”